Literature DB >> 24952479

Botulinum toxin for symptomatic therapy in multiple sclerosis.

Michelle H Cameron1, Francois Bethoux, Nina Davis, Meredith Frederick.   

Abstract

Botulinum toxin (BT) is a neurotoxin that paralyzes muscles by inhibiting release of acetylcholine from presynaptic vesicles at the neuromuscular junction. In people with multiple sclerosis (MS), clinical experience and research studies show that local injection of minute quantities of BT can temporarily control skeletal muscle spasticity, bladder detrusor hyperreflexia, and tremor. Specifically, BT injections have been shown to reduce muscle tone and improve passive function, and possibly improve active function, in patients with spasticity. Injection of BT into the bladder wall is a uniquely effective, safe, and durable treatment in patients with neurogenic detrusor hyperreflexia due to MS who have insufficient response or who do not tolerate oral antimuscarinic medications. This procedure has markedly reduced the need for indwelling catheters and bladder surgery. In addition, a recent study suggests BT may be effective for select patients with MS-associated upper extremity tremor. Appropriate use of BT can improve quality of life for many patients with MS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24952479     DOI: 10.1007/s11910-014-0463-7

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  30 in total

1.  Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

Authors:  Sender Herschorn; Jerzy Gajewski; Karen Ethans; Jacques Corcos; Kevin Carlson; Gregory Bailly; Robert Bard; Luc Valiquette; Richard Baverstock; Lesley Carr; Sidney Radomski
Journal:  J Urol       Date:  2011-04-16       Impact factor: 7.450

2.  Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.

Authors:  Hann-Chorng Kuo
Journal:  Neurourol Urodyn       Date:  2011-05-10       Impact factor: 2.696

3.  Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Authors:  David Ginsberg; Angelo Gousse; Veronique Keppenne; Karl-Dietrich Sievert; Catherine Thompson; Wayne Lam; Mitchell F Brin; Brenda Jenkins; Cornelia Haag-Molkenteller
Journal:  J Urol       Date:  2012-04-12       Impact factor: 7.450

4.  Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Authors:  Brigitte Schurch; Marianne de Sèze; Pierre Denys; Emmanuel Chartier-Kastler; Francois Haab; Karel Everaert; Pierre Plante; Brigitte Perrouin-Verbe; Catherine Kumar; Stephanie Fraczek; Mitchell F Brin
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

Review 5.  Multiple sclerosis and the urologist.

Authors:  S E Litwiller; E M Frohman; P E Zimmern
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

6.  Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis.

Authors:  C E Clarke
Journal:  Eur J Neurol       Date:  1997-01       Impact factor: 6.089

7.  Prevalence and treatment of spasticity reported by multiple sclerosis patients.

Authors:  M A Rizzo; O C Hadjimichael; J Preiningerova; T L Vollmer
Journal:  Mult Scler       Date:  2004-10       Impact factor: 6.312

8.  Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques.

Authors:  Alessandro Picelli; Davide Lobba; Alessandro Midiri; Paolo Prandi; Camilla Melotti; Silvia Baldessarelli; Nicola Smania
Journal:  Clin Rehabil       Date:  2013-08-14       Impact factor: 3.477

9.  Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity.

Authors:  S Gaillet; P Bardot; B Bernuz; R Boissier; K Lenne-Aurier; I Thiry-Escudier; H Tournebise; E Lechevallier; G Karsenty
Journal:  Prog Urol       Date:  2012-11-13       Impact factor: 0.915

10.  Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment.

Authors:  Andrés Labiano-Fontcuberta; Julián Benito-León
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-14
View more
  9 in total

1.  Spastic Paralysis of the Elbow and Forearm.

Authors:  Idris Gharbaoui; Katarzyna Kania; Patrick Cole
Journal:  Semin Plast Surg       Date:  2016-02       Impact factor: 2.314

Review 2.  Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions.

Authors:  Anton Bespalov; Liudmila Mus; Edwin Zvartau
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02-10       Impact factor: 3.000

3.  Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Authors:  Molly S Moritz; William H Tepp; Heather N'te Inzalaco; Eric A Johnson; Sabine Pellett
Journal:  Toxicon       Date:  2019-06-07       Impact factor: 3.033

4.  In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.

Authors:  Sabine Pellett; William H Tepp; Regina C M Whitemarsh; Marite Bradshaw; Eric A Johnson
Journal:  Toxicon       Date:  2015-06-27       Impact factor: 3.033

Review 5.  Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.

Authors:  Dirk Dressler; Roongroj Bhidayasiri; Saeed Bohlega; Abderrahmane Chahidi; Tae Mo Chung; Markus Ebke; L Jorge Jacinto; Ryuji Kaji; Serdar Koçer; Petr Kanovsky; Federico Micheli; Olga Orlova; Sebastian Paus; Zvezdan Pirtosek; Maja Relja; Raymond L Rosales; José Alberto Sagástegui-Rodríguez; Paul W Schoenle; Gholam Ali Shahidi; Sofia Timerbaeva; Uwe Walter; Fereshte Adib Saberi
Journal:  J Neurol       Date:  2016-10-27       Impact factor: 4.849

6.  Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.

Authors:  Pamela Latino; Letizia Castelli; Luca Prosperini; Maria Rita Marchetti; Carlo Pozzilli; Morena Giovannelli
Journal:  Neurol Sci       Date:  2017-08-01       Impact factor: 3.307

7.  Total knee arthroplasty in multiple sclerosis.

Authors:  Kaitlyn E Hughes; Darren Nickel; Tanner Gurney-Dunlop; Katherine B Knox
Journal:  Arthroplast Today       Date:  2016-03-23

Review 8.  The Beneficial and Debilitating Effects of Environmental and Microbial Toxins, Drugs, Organic Solvents and Heavy Metals on the Onset and Progression of Multiple Sclerosis.

Authors:  Mahmood Y Hachim; Noha M Elemam; Azzam A Maghazachi
Journal:  Toxins (Basel)       Date:  2019-03-05       Impact factor: 4.546

9.  Synergic use of botulinum toxin injection and radial extracorporeal shockwave therapy in Multiple Sclerosis spasticity.

Authors:  Cinzia Marinaro; Cosimo Costantino; Oriana D'Esposito; Marianna Barletta; Angelo Indino; Gerardo De Scorpio; Antonio Ammendolia
Journal:  Acta Biomed       Date:  2021-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.